Dupilumab vs placebo was linked to improved health-related quality of life and respiratory symptoms in patients with COPD and T2 inflammation.

Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

With 30% of COPD cases misdiagnosed, experts call for improved diagnostic strategies, better disease classification, and ...

Dupilumab is safe and efficacious for the treatment of atopic dermatitis for 3 years among pediatric patients aged 6 months to 11 years.

Dupilumab rapidly treated and maintained improvements in lichenification, a type of skin thickening from repetitive ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks ... evaluating the investigational use of Dupixent ® (dupilumab) in adults with moderate-to-severe bullous ...

Lebrikizumab is comparable or superior to many advanced systemic monotherapies for the short-term treatment of atopic dermatitis.

Positive results from ADEPT phase 2/3 study of Dupixent in adults with moderate-to-severe bullous pemphigoid presented at AAD: Paris Tuesday, March 11, 2025, 14:00 Hrs [IST] Posit ...

To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation. In addition to ...

To date, dupilumab has been studied across more than 60 clinical studies involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation. In addition to the ...

To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation. In addition to the ...